SEC Comment Letter for PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981) (CNSY) — May 24, 2016
PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981)
Date: May 24, 2016 · CIK: 0001095981 · Accession: 0000000000-16-077773
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-210628
Letter
Mail Stop 3030 May 2 4, 2016 Marc H. Hedrick, MD President and Chief Executive Officer Cytori Therapeutics, Inc. 3020 Callan Road San Diego, CA 92121
Re: Cytori Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S -1 Filed May 10, 2016 File No. 333-210628
Dear Dr. Hedrick :
We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the requested information . If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to the registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our May 3, 2016 letter.
Use of Proceeds
1. We note your response to prior comment 3. If material amounts of other fu nds are necessary to accomplish the purposes for which the proceeds are to be obtained, state the amounts and intended sources of such funds needed for each specified purpose and the sources thereof.
Exhibit 5.1
2. Please revise to opine that the rights a nd warrants are binding obligations of the registrant under the law of the jurisdiction governing those secur ities. Please refer to Section II.B.1.f. of Staff Legal Bulletin No. 19 available on our website .
Marc H. Hedrick , MD Cytori Therapeutics, Inc. May 2 4, 2016 Page 2
Please contact Tom Jones at (202) 551 -3602 or Tim Buchmi ller, Senior Attorney, at (202) 551-3635 with any questions.
Sincerely,
/s/ Tim Buchmiller for
Show Raw Text
Mail Stop 3030 May 2 4, 2016 Marc H. Hedrick, MD President and Chief Executive Officer Cytori Therapeutics, Inc. 3020 Callan Road San Diego, CA 92121 Re: Cytori Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S -1 Filed May 10, 2016 File No. 333-210628 Dear Dr. Hedrick : We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information . If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to the registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our May 3, 2016 letter. Use of Proceeds 1. We note your response to prior comment 3. If material amounts of other fu nds are necessary to accomplish the purposes for which the proceeds are to be obtained, state the amounts and intended sources of such funds needed for each specified purpose and the sources thereof. Exhibit 5.1 2. Please revise to opine that the rights a nd warrants are binding obligations of the registrant under the law of the jurisdiction governing those secur ities. Please refer to Section II.B.1.f. of Staff Legal Bulletin No. 19 available on our website . Marc H. Hedrick , MD Cytori Therapeutics, Inc. May 2 4, 2016 Page 2 Please contact Tom Jones at (202) 551 -3602 or Tim Buchmi ller, Senior Attorney, at (202) 551-3635 with any questions. Sincerely, /s/ Tim Buchmiller for Amanda Ravitz Assistant Director Office of Electronics and Machinery cc: Jeffrey T. Baglio, Esq.